Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study.

Diabetol Metab Syndr · 2025 · PMC11998411 · PMID 40229852

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

only marginally significantp < 0.1so close (0.05 < p ≤ 0.1)

However, in this study, there was a significant difference of changes in SD between the semaglutide and DPP-4 inhibitors groups, but the difference in CV changes was only marginally significant (p < 0.1).

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.